Human IGF2R (aa 161-291) Control Fragment Recombinant Protein | Invitrogen RP-102439 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

protein

product name :

Human IGF2R (aa 161-291) Control Fragment Recombinant Protein

catalog :

RP-102439

quantity :

100 uL

price :

US 259.00

product information

Product Type :

Protein

Product Name :

Human IGF2R (aa 161-291) Control Fragment Recombinant Protein

Catalog # :

RP-102439

Quantity :

100 uL

Price :

US 259.00

Clonality :

Recombinant

Purity :

purified

Reactivity :

Human

Applications :

Blocking Assay: Assay-dependent, Control: Assay-dependent

Species :

Human

Storage :

-20 C, Avoid Freeze/Thaw Cycles

Description :

Lysosomal enzymes containing one or two mannose 6-phosphate (man6P) moieties are moved about in the cell by two distinct but interconnected cycles by means of approximately 300 kDa cation independent mannose 6-phospate receptors (CI-MPR). The biosynthetic cycle refers to the MPR transport of newly synthesized lysosomal enzymes from the trans Golgi network to late endosomes or early lysosomes. The endocytic cycle transports extracellular lysosomal enzymes from the plasma membrane via clathrin-coated vesicles to early endosomes. The entire pool of MPRs cycles between these cellular compartments every 3 hours. The steady state distribution of MPR's is predominantly within late endosomes, fewer in the trans Golgi network and approximately 10 % at cell surface. In addition to its man6P binding activity, the MPR contains a separate binding site for the type II insulin-like growth factor and is capable of binding both man6P and IGF-II simultaneously. An approximately 240 kDa soluble, truncated form, representing the extracellular domain of the protein, has also been found circulating in serum and is capable of binding both ligands.

Format :

Liquid

Applications w/Dilutions :

Blocking Assay: Assay-dependent, Control: Assay-dependent

Aliases :

300 kDa mannose 6-phosphate receptor; AI661837; cation-independent mannose 6-phosphate receptor; cation-independent mannose 6-phosphate receptor protein; cation-independent mannose-6-phosphate receptor; cation-independent MPR; CD222; CI Man-6-P receptor; CI-M6PR; CIMPR; CI-MPR; Igf2r; IGF-II receptor; IGF-II/CI-MPR; Igfr2; insulin like growth factor 2 receptor; insulin-like growth factor 2 receptor; Insulin-like growth factor II receptor; insulin-like growth factor receptor type 2; M6P; M6P/IGF2 receptor; M6P/IGF2R; M6PR; M6P-R; mannose-6-phosphate receptor, cation independent; mannose-6-phosphate/insulin-like growth factor II receptor; MPR 300; MPR1; MPR300; MPRI; similar to mannose-6-phosphate/insulin-like growth factor II receptor